Effect of high dose of pyridoxine on mammary tumorigenesis

Nutr Cancer. 2005;53(2):202-7. doi: 10.1207/s15327914nc5302_9.

Abstract

The effect of high-dose pyridoxine (PN) on mammary tumorigenesis was examined in female Sprague-Dawley rats. The first mammary tumors appeared between 84 and 90 days after 7,12-dimethylbenzanthracene treatment. There was no effect of PN level on tumor incidence at 90 days but at 98, 104, and 111 days. Tumor incidence was lower in the high-dose group (35 mg PN/kg diet) compared with the controls (7 mg PN/kg diet). All tumors were identified as adenocarcinoma and most as papillary type. The number of microcarcinomas in mammary glands of the 35-mg PN group tended to be reduce than that of the 7-mg group. The number of proliferating Ki67-positive cells was significantly reduced by supplementation with PN.

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / epidemiology
  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Female
  • Ki-67 Antigen
  • Mammary Neoplasms, Experimental / drug therapy*
  • Mammary Neoplasms, Experimental / epidemiology
  • Pyridoxine / therapeutic use*
  • Random Allocation
  • Rats
  • Rats, Sprague-Dawley
  • Time Factors
  • Vitamin B Complex / therapeutic use*

Substances

  • Antineoplastic Agents
  • Ki-67 Antigen
  • Vitamin B Complex
  • Pyridoxine